E

Exelixis

D
EXEL
USD
0.03
(0.1119%)
Market Closed
152,407.00
Volume
1.385
EPS
-
Div Yield
23.138
P/E
7,656,156,299.00
Market Cap
Today
0.1119%
1 Week
2.014%
1 Month
0.978%
6 Months
14.408%
12 Months
25.303%
Year To Date
11.857%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ARWR
0.35
(1.6851%)
USD
I
INCY
1.67
(2.5625%)
USD
GSK
GSK
-0.78
(-1.8383%)
USD
MRK
MRK
-1.44
(-1.2137%)
USD
BMY
BMY
-0.72
(-1.4475%)
USD
B
BCRX
0.195
(2.4482%)
USD
REGN
REGN
11.33
(0.9948%)
USD
AMGN
AMGN
3.02
(0.9071%)
USD

Title:
Exelixis

Sector:
Healthcare
Industry:
Biotechnology
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Do you need help or have a question?
Contact Us